the Prostate Cancer Prevention Trial (PCPT) using the drug finasteride, has provided the urologic community with the first evidence that a chemopreventive agent can reduce the risk of developing ...

D'Amico AV and Roehrborn CG (2007) Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol ...

Finasteride was initially approved by the Food and Drug Administration (FDA) to treat benign prostatic hyperplasia (BPH), which is an enlarged prostate gland. By lowering DHT levels, finasteride ...

The 5α reductase inhibitor finasteride is an effective chemopreventative agent against prostate cancer. However, the use of finasteride in the general male population remains low, in part due to ...

Finasteride has two FDA-approved usages. One is to help treat benign prostatic hyperplasia (aka enlarged prostate). Second, finasteride, a 5-alpha-reductase, helps promote hair growth by blocking ...

The 24.8% relative risk reduction in prostate cancer seen in the finasteride arm prompted the early termination of the study on February 21, 2003, 15 months before its anticipated completion.